Recently, a large-scale randomized controlled trial study, EMPA-REG OUTCOME [32], showed that empagliflozin, an SGLT2 inhibitor, decreased composite cardiovascular events, mainly due to reduction of heart failure by a hemodynamic effect including osmotic diuresis rather than reduction of blood pressure [33]. The gene discussed is SLC5A2; the disease is heart failure.